Grant Street Asset Management Inc. Sells 539 Shares of Johnson & Johnson (NYSE:JNJ)

Grant Street Asset Management Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,377 shares of the company’s stock after selling 539 shares during the quarter. Grant Street Asset Management Inc.’s holdings in Johnson & Johnson were worth $488,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of JNJ. Vista Investment Partners II LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at $523,000. Morton Community Bank lifted its position in Johnson & Johnson by 1.4% during the fourth quarter. Morton Community Bank now owns 25,022 shares of the company’s stock worth $3,619,000 after purchasing an additional 350 shares during the period. Tortoise Investment Management LLC lifted its position in Johnson & Johnson by 3.3% during the fourth quarter. Tortoise Investment Management LLC now owns 3,266 shares of the company’s stock worth $472,000 after purchasing an additional 103 shares during the period. Independent Advisor Alliance lifted its holdings in shares of Johnson & Johnson by 6.3% in the fourth quarter. Independent Advisor Alliance now owns 93,481 shares of the company’s stock worth $13,519,000 after acquiring an additional 5,509 shares during the last quarter. Finally, Altiora Financial Group LLC lifted its holdings in shares of Johnson & Johnson by 26.5% in the fourth quarter. Altiora Financial Group LLC now owns 2,262 shares of the company’s stock worth $327,000 after acquiring an additional 474 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent research reports. Raymond James lowered their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.6 %

JNJ stock opened at $166.81 on Monday. The firm has a 50 day moving average of $152.95 and a 200 day moving average of $156.24. The stock has a market capitalization of $401.61 billion, a PE ratio of 25.08, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.